Search research articles
Contact Us
Filters
Showing results (151-160 of 160) with videos related to
Page
of 16
Sort By:
You have reached the last page of results.
This site can display upto 160 results.
European Journal of Cancer (Oxford, England : 1990)
|
May 20, 2003
Cisplatin, doxorubicin and ifosfamide in carcinosarcoma of the female genital tract. A phase II study of the European Organization for Research and Treatment of Cancer Gynaecological Cancer Group (EORTC 55923)
R E N van Rijswijk, J B Vermorken, N Reed, et al.
Gynecologic Oncology
|
May 24, 2001
Bleomycin, methotrexate, and CCNU in locally advanced or recurrent, inoperable, squamous-cell carcinoma of the vulva: an EORTC Gynaecological Cancer Cooperative Group Study. European Organization for Research and Treatment of Cancer
H C Wagenaar, N Colombo, I Vergote, et al.
Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology
|
October 16, 2007
Italian position statement on hormone replacement therapy following the National Conference on Menopause and Hormone Replacement Therapy, Villa Tuscolana, Frascati (Rome), May 8-9, 2007
Andrea Genazzani, Marco Gambacciani, Tommaso Simoncini, et al.
European Journal of Gynaecological Oncology
|
August 15, 2001
Phase II study of a combination of cyclophosphamide, adriamycin and cisplatin in advanced fallopian tube carcinoma. An EORTC gynecological cancer group study. European Organization for Research and Treatment of Cancer
H C Wagenaar, S Pecorelli, I Vergote, et al.
British Journal of Cancer
|
June 29, 2013
Mammaglobin B (SCGB2A1) is a novel tumour antigen highly differentially expressed in all major histological types of ovarian cancer: implications for ovarian cancer immunotherapy
S Bellone, R Tassi, M Betti, et al.
Journal of the National Cancer Institute
|
May 4, 2000
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results
M J Piccart, K Bertelsen, K James, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
December 6, 2003
Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer
M J Piccart, K Bertelsen, G Stuart, et al.
Oncogene
|
December 6, 2011
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer
E S Ratner, F K Keane, R Lindner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 22, 2005
2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004)
A du Bois, M Quinn, T Thigpen, et al.
The Journal of Nutrition, Health & Aging
|
December 22, 2016
Building Bridges for Innovation in Ageing: Synergies between Action Groups of the EIP on AHA
J Bousquet, M Bewick, A Cano, et al.
Page
of 16
Search research articles
Search
Showing results (151-160 of 160) with videos related to
Sort By:
Page
of 16
You have reached the last page of results.
This site can display upto 160 results.
European Journal of Cancer (Oxford, England : 1990)
|
May 20, 2003
Cisplatin, doxorubicin and ifosfamide in carcinosarcoma of the female genital tract. A phase II study of the European Organization for Research and Treatment of Cancer Gynaecological Cancer Group (EORTC 55923)
R E N van Rijswijk, J B Vermorken, N Reed, et al.
Gynecologic Oncology
|
May 24, 2001
Bleomycin, methotrexate, and CCNU in locally advanced or recurrent, inoperable, squamous-cell carcinoma of the vulva: an EORTC Gynaecological Cancer Cooperative Group Study. European Organization for Research and Treatment of Cancer
H C Wagenaar, N Colombo, I Vergote, et al.
Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology
|
October 16, 2007
Italian position statement on hormone replacement therapy following the National Conference on Menopause and Hormone Replacement Therapy, Villa Tuscolana, Frascati (Rome), May 8-9, 2007
Andrea Genazzani, Marco Gambacciani, Tommaso Simoncini, et al.
European Journal of Gynaecological Oncology
|
August 15, 2001
Phase II study of a combination of cyclophosphamide, adriamycin and cisplatin in advanced fallopian tube carcinoma. An EORTC gynecological cancer group study. European Organization for Research and Treatment of Cancer
H C Wagenaar, S Pecorelli, I Vergote, et al.
British Journal of Cancer
|
June 29, 2013
Mammaglobin B (SCGB2A1) is a novel tumour antigen highly differentially expressed in all major histological types of ovarian cancer: implications for ovarian cancer immunotherapy
S Bellone, R Tassi, M Betti, et al.
Journal of the National Cancer Institute
|
May 4, 2000
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results
M J Piccart, K Bertelsen, K James, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
December 6, 2003
Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer
M J Piccart, K Bertelsen, G Stuart, et al.
Oncogene
|
December 6, 2011
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer
E S Ratner, F K Keane, R Lindner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 22, 2005
2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004)
A du Bois, M Quinn, T Thigpen, et al.
The Journal of Nutrition, Health & Aging
|
December 22, 2016
Building Bridges for Innovation in Ageing: Synergies between Action Groups of the EIP on AHA
J Bousquet, M Bewick, A Cano, et al.
Page
of 16